Glycemic control as a part of coronary stenosis prevention strategy in type 2 diabetes patients before and after transcutaneous coronary intervention
- Authors: Salukhov V.V1, Kadin S.V1, Agliullin A.F1
-
Affiliations:
- S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federation
- Issue: Vol 18, No 10 (2016)
- Pages: 24-28
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94543
- ID: 94543
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
V. V Salukhov
S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federation
Email: vlasaluk@yandex.ru
д-р мед. наук, нач. 1-й каф. (терапии усовершенствования врачей) ФГБВОУ ВО им. С.М.Кирова 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6
S. V Kadin
S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federationканд. мед. наук, преподаватель 1-й каф. (терапии усовершенствования врачей) ФГБВОУ ВО им. С.М.Кирова 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6
A. F Agliullin
S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federationслушатель клин. ординатуры ФГБВОУ ВО им. С.М.Кирова 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6
References
- Hurst R.T, Lee R.W. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 2003; 139: 824-34.
- Kip K.E, Faxon D.P, Detre K.M et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation1996; 94: 1818-25.
- Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
- Stamler J, Vaccaro O, Neaton J.D et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993; 16: 434-44.
- Alderman E.L, Corley S.D, Fisher L.D et al. Five - year angiographic follow - up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993; 22: 1141-54.
- Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995; 75: 894-903.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53.
- The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta - analysis of 102 prospective studies. Lancet 2010; 375 (9733): 2215-22.
- Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
- Wannamethee S.G, Shaper A.G, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart 2004; 90: 1398-403.
- Fisher M. Diabetes: can we stop the time bomb? Heart 2003; 89 (Suppl. 2): 28-30.
- Акчурин Р.С., Власова Э.Е., Мершин К.В. Сахарный диабет и хирургическое лечение ишемической болезни сердца. Вестн. РАМН. 2012; 1: 14-9.
- Дедов И.И. Диабет как фактор риска сердечно - сосудистых заболеваний. Сердечная недостаточность. 2003; 3: 16-9.
- Soinio M, Marniemi J, Laakso M et al. High - sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. A 7-year follow - up study. Diabetes Care 2006; 29 (2): 329-33.
- Торшхоева Х.Н., Ткачева О.Н., Подпругина Н.Г. и др. Диабетическая кардиоваскулярная автономная нейропатия. Сахарный диабет. 2004; 1: 38-9.
- Radermecker R.P, Philips J.C, Jandrain B et al. Blood glucose control and cardiovascular disease in patiens with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials. Rev Med Liege 2008; 63 (7-8): 511-8.
- Dluhy R.G, Mc Mahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358 (24): 2630-3.
- Le Roith D, Fonseca V, Vinik A. Metabolic memory in diabetes - focus on insulin. Diabetes Metab Res Rev 2005; 21 (2): 85-90.
- Mick M.J, Piedmonte M.R, Arnold A.M et al. Risk stratification for long - term outcome after elective coronary angioplasty: a multivariate analysis of 5,000 patients. J Am Coll Cardiol 1994; 24: 74-80.
- The BARI Investigators. The Final 10-Year Follow - Up Results From the BARI Randomized Trial. J Am Coll Cardiol 2007; 49: 1600-6.
- Mathew V, Gersh B.J, Williams B.A et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109: 476-80.
- West N.E, Ruygrok P.N, Disco C.M et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 109: 867-73.
- Mazeika P, Prasad N, Bui S et al. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003; 145: 1013-21.
- Holmes D.R Jr, Leon M.B, Moses J.W et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus - eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634-40.
- Byrne R.A, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going. Eur Heart J 2015; 36 (47): 3320-31.
- Legrand V. Therapy insight: Diabetes and drug - eluting stents. Nat Clin Pract Cardiovasc Med 2007; 4: 143-50.
- Fröbert O, Lagerqvist B, Carlsson J et al. Differences in restenosis rate with different drug - eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009; 53 (18): 1660-7.
- Hong S.J, Kim M.H, Ahn T.H et al. Multiple predictors of coronary restenosis after drug - eluting stent implantation in patients with diabetes. Heart 2006; 92: 1119-24.
- Svedman C, Ekqvist S, Moller H et al. A correlation found between contact allergy to stent material and restenosis of the coronary arteries. Contact Dermatitis 2009; 60: 158-64.
- Березовская Г.А., Ганюков В.И., Карпенко М.А. Рестеноз и тромбоз внутри стента: патогенетические механизмы развития и прогностические маркеры. Рос. кардиол. журн. 2012; 6 (98): 91-5.
- Tian F, Chen Y, Liu H et al. Assessment of characteristics of neointimal hyperplasia after drug - eluting stent implantation in patients with diabetes mellitus: an optical coherence tomography analysis. Cardiology 2014; 128 (1): 34-40.
- Ломоносова А.А., Григорова С.Ю., Афанасьев Ю.И. Проблема рестеноза после чрескожных внутрикоронарных вмешательств и перспективы его профилактики с помощью генотерапевтических воздействий. Науч. ведомости. 2010; 4 (75; Вып. 9).
- Aronson D, Bloomgarden Z, Rayfield E.J. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528-35.
- Kereiakes D.J, Young J.J. Percutaneous coronary revascularization of diabetic patients in the era of drug - eluting stents. Rev Cardiovasc Med 2005; 6 (Suppl. 1): S48-58.
- Beckman J.A, Creager M.A, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
- Sobel B.E. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 1999; 99: 2496-8.
- Yusuf S, Zhao F, Mehta S.R et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
- Choi D, Kim S.K, Choi S.H et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-60.
- Dibra A, Kastrati A, Mehilli J et al. Paclitaxel - eluting or sirolimus - eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-70.
- Corpus R.A, George P.B, House J.A et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43: 8-14.
- Волкова Е.А., Ворохобина Н.В., Малыгина О.Ф. Модификация образа жизни, обучение и самоконтроль - важные компоненты лечения сахарного диабета и улучшения качества жизни пациентов. // Consilium Medicum. 2015; 17 (1): 54-62.
- Caswell M, Frank J, Viggiani M.T et al. Accuracy and user performance evaluation of a blood glucose monitoring system. Diabetes Technol Ther 2015; 17 (3): 152-8.
- Редькин Ю.А., Богомолов В.В., Древаль А.В. Влияние различных факторов на эффективность самоконтроля при сахарном диабете. // Consilium Medicum. 2011; 13 (12): 54-7.
- Dunne N, Viggiani M.T, Pardo S et al. Accuracy Evaluation of CONTOUR®PLUS Compared With Four Blood Glucose Monitoring Systems. Diabetes Ther 2015; 6 (3): 377-88.
- Аметов А.С., Черникова Н.А. Гликемический контроль у пациентов с сахарным диабетом типа 2. // Consilium Medicum. 2016; 18 (4): 24-7.